Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
indeed. it looks like DEAR is holding steady its 1.75$ range. easy sideways moving. nothing bad about it.
Jazz Pharmaceuticals Announces New Patent Issued For Sodium Oxybate
PALO ALTO, Calif., Dec. 21, 2010 /PRNewswire/ — Jazz Pharmaceuticals, Inc. (JAZZ: 19.97 0.00 0.00%) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent related to Xyrem® (sodium oxybate) oral solution titled “Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy.” The new patent, number 7,851,506, is also listed in the FDA’s Approved Drug Products List (the Orange Book).
In addition to the newly issued patent, Xyrem is protected by seven other patents related to the product’s formulation and Jazz Pharmaceuticals’ distribution system. Six issued patents are now listed in the Orange Book. These patents expire from 2019 to 2024.
“Enhancing and enforcing the intellectual property coverage for Xyrem is an important strategic priority for our company,” said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.
same too you . some nice profit out of this. yeeey.
RPC 0.58$ wowzers. 200 day ma is at 0.75$.
LCC 10.06$ is hanging in there. i think its waiting for the 200 day MA to catch up. they selling shares just right now. could be a chance to catch cheap ones in the long term.
US Airways, Inc. Announces $340 Million Aircraft Financing
TEMPE, Ariz.--(BUSINESS WIRE)--US Airways, Inc. (“US Airways” or the “Company”), a wholly-owned subsidiary of US Airways Group, Inc. (NYSE: LCC) (“US Airways Group”), announced today its intention to make an offering, subject to market and other conditions, of enhanced equipment trust certificates (the “Certificates”) in the aggregate principal amount of approximately $340 million. The Company intends to use the proceeds from the offering to refinance eight Airbus aircraft currently owned by US Airways and use the balance, if any, for general corporate purposes.
The $340 million financing will be comprised of approximately $263 million of Class A certificates with a final expected distribution date of April 22, 2023 and approximately $77 million of Class B certificates with a final expected distribution date of April 22, 2017.
Morgan Stanley & Co. Incorporated (“Morgan Stanley”) will act as structuring agent for the offering. Morgan Stanley, Citigroup Global Markets Inc. (“Citigroup”) and Credit Suisse Securities (USA) LLC (“Credit Suisse”) will act as the joint book-running managers for the offering; Merrill Lynch, Pierce, Fenner & Smith Incorporated will act as a co-manager for the offering.
The Certificates will be offered under the Company’s existing effective shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission. A prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the Securities and Exchange Commission. When available, copies of both the prospectus supplement and the accompanying prospectus may be obtained from Morgan Stanley (tel: 1-866-718-1649), from Citigroup (tel: 1-212-723-6171) or from Credit Suisse (tel: 1-800-221-1037).
DEAR 1.81
Earnings expected January 17 2011.
DEAR 1.81$ Thanks for the earnings date, added to sticky post.
lol @ your new name MNI 4.87$
thanks for the MNI charts. buying volume looks pretty well. target 200 day MA 6.50-6.90$ on the weekly?
# 52 week range 2.60 - 7.16
Vical's Vaxfectin(R) Demonstrates Potential as "Universal" Adjuvant
Quote:Press Release Source: Vical Incorporated On Monday December 13, 2010, 6:30 am EST
SAN DIEGO, Dec. 13, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL - News) announced today that the company's Vaxfectin(R) adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin(R) has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models. Vaxfectin(R)-formulated H5N1 influenza DNA vaccines were well-tolerated and elicited durable immune responses within the predicted protective range in initial human studies.
"Vaxfectin(R) has many of the desired features of a successful adjuvant," said Alain P. Rolland, Pharm.D., Ph.D., Vical's Executive Vice President of Product Development, "including the ability to significantly improve immune responses and favor specific types of immune responses. With a promising safety profile in preclinical and initial clinical studies, ease of formulation, stability and low manufacturing costs, Vaxfectin(R) is well-positioned as a potential 'universal' adjuvant for either immune enhancement or dose sparing applications in a broad range of infectious disease and cancer vaccines. A comprehensive new review of Vaxfectin(R) results published in the journal Expert Opinion on Drug Delivery[1] details Vaxfectin(R)'s development to date and should help us expand our outreach to potential licensees."
Vaxfectin(R) has been shown in multiple animal models to significantly increase the antibody and T-cell immune responses to antigens expressed from plasmid DNA vaccines. Results from two Phase 1 clinical trials of Vaxfectin(R)-formulated H5N1 influenza DNA vaccines demonstrated strong antibody responses and achieved T-cell responses in 75% to 100% of subjects in various dose cohorts. Vaxfectin(R) has demonstrated similar effect with protein-based vaccines, and the formulation can be adjusted to favor specific immune responses. The current publication reviews non-clinical immunological and efficacy studies of Vaxfectin(R) in several infectious disease and cancer models, preclinical safety and toxicology studies, clinical development of Vaxfectin(R)-formulated DNA vaccines, and studies of Vaxfectin(R)'s mechanism of action.
http://finance.yahoo.com/news/Vicals-VaxfectinR-pz-804827718.html?x=0&.v=1
Vical's Vaxfectin(R) Demonstrates Potential as "Universal" Adjuvant
Press Release Source: Vical Incorporated On Monday December 13, 2010, 6:30 am EST
SAN DIEGO, Dec. 13, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL - News) announced today that the company's Vaxfectin(R) adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin(R) has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models. Vaxfectin(R)-formulated H5N1 influenza DNA vaccines were well-tolerated and elicited durable immune responses within the predicted protective range in initial human studies.
"Vaxfectin(R) has many of the desired features of a successful adjuvant," said Alain P. Rolland, Pharm.D., Ph.D., Vical's Executive Vice President of Product Development, "including the ability to significantly improve immune responses and favor specific types of immune responses. With a promising safety profile in preclinical and initial clinical studies, ease of formulation, stability and low manufacturing costs, Vaxfectin(R) is well-positioned as a potential 'universal' adjuvant for either immune enhancement or dose sparing applications in a broad range of infectious disease and cancer vaccines. A comprehensive new review of Vaxfectin(R) results published in the journal Expert Opinion on Drug Delivery[1] details Vaxfectin(R)'s development to date and should help us expand our outreach to potential licensees."
Vaxfectin(R) has been shown in multiple animal models to significantly increase the antibody and T-cell immune responses to antigens expressed from plasmid DNA vaccines. Results from two Phase 1 clinical trials of Vaxfectin(R)-formulated H5N1 influenza DNA vaccines demonstrated strong antibody responses and achieved T-cell responses in 75% to 100% of subjects in various dose cohorts. Vaxfectin(R) has demonstrated similar effect with protein-based vaccines, and the formulation can be adjusted to favor specific immune responses. The current publication reviews non-clinical immunological and efficacy studies of Vaxfectin(R) in several infectious disease and cancer models, preclinical safety and toxicology studies, clinical development of Vaxfectin(R)-formulated DNA vaccines, and studies of Vaxfectin(R)'s mechanism of action.
4-Star Stocks Poised to Pop: Power-One
By Brian D. Pacampara | More Articles
December 13, 2010 | Comments (0)
Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, power management solutions provider Power-One (Nasdaq: PWER) earned a respected four-star ranking.
With that in mind, let's take a closer look at Power-One's business and see what CAPS investors are saying about the stock right now.
Power-One facts
Headquarters (Founded) Camarillo, Calif. (1973)
Market Cap $1.2 billion
Industry Electronic components
Trailing-12-Month Revenue $823.4 million
Management
CEO Richard Thompson (since February 2008)
CFO Gary Larsen (since August 2010)
Return on Capital (Average, Past 3 Years) 14%
Cash/Debt $194.6 million / $39.7 million
Competitors
Emerson Electric (NYSE: EMR)
General Electric (NYSE: GE)
Tyco Electronics (NYSE: TEL)
Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.
On CAPS, 90% of the 318 members who have rated Power-One believe the stock will outperform the S&P 500 going forward. These bulls include Clint35 and All-Star IgnorantFool77, who is ranked in the top 5% of our community.
Just last month, Clint35 touched on Power-One's bright prospects: "Small company with big potential. ... Assuming the solar power market grows this company definitely will too, because inverters are almost always used on any house or building that's powered by solar."
As the world's second-largest supplier of photovoltaic inverters, Power-One is becoming an increasingly popular greenish growth play in our community. Currently, the stock even trades at a forward P/E (8.6) discount giant power management specialists like Emerson (15.2), GE (13.9), Siemens (NYSE: SI) (11.8), and Tyco Electronics (9.5).
CAPS All-Star IgnorantFool77 elaborates on the bull case:
Let's talk about the business for a moment. [Its] focus is on energy conversion and energy management. It specifically is a leader in the area of energy efficient inverters. There is a race on right now across most industries to demonstrate their ability to 'go green,' and become more energy efficient. This is not only looks good to the press it looks good on the bottom line.
What do you think about Power-One, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!
http://www.fool.com/investing/general/2010/12/13/4-star-stocks-poised-to-pop-power-one.aspx
DEAR 1.77$ the financials start the engines. yes sir!
DEAR 1.77$ the financials start the engines. yes sir!
shure but now with the Ipad, things could improove. you know this stock has a history of large gains, that should be the focus imo. things will change in this industry, sometimes changes can build a new chance.
McClatchy says ad trends are improving
December 8, 2010 9:59 AM ET
NEW YORK (AP) - McClatchy Co. says declines in advertising continue to slow in the fourth quarter.
Newspapers are struggling to arrest a nearly four-year slide in ad revenue as more advertisers turn to online destinations like Google and Facebook.
With the worst of the recession over, publishers are reporting smaller declines in print revenue. But they haven't seen the kind of rebound that would make up for steep declines last year.
McClatchy, which publishes The Sacramento Bee, The Miami Herald and other dailies, says ad revenue in the first two months of the quarter slipped 5.8 percent compared with the same two months of last year.
In the third quarter, McClatchy's ad revenue was down 6.4 percent from the previous year.
The company's stock jumped 17 cents, or 4.8 percent, to $3.72 in morning trading.
http://articles.moneycentral.msn.com/news/article.aspx?feed=AP&date=20101208&id=12491910
they still struggling but this thing can move.
MNI at 4.50$ resistance looks like it will go higher imo.
MNI 4.48$ Newspaper Company wich can make good moves. at 4.50$ resistance.
it went from 0.50$ 2009 to 7.16$ 2010. it has found good support this year at 2.65$ and currently its in a uptrend.
GL
yes thanks sir!
I sold it.
was looking for aprooval on monday or so... :(
but still, profit is profit! :) i could get some.
CPIX 7.83$ ideed looking good. this stock has a low price target of 9$ and solid financials. this is what i know.
still time to get in.
CPIX 8.00$ today is the day. Hopefully
hopefully , thoose 7.20$ is a p.i.t.a. lol and the 200 day MA knocking from aboove.
thanks a lot for the charts
JAZZ HOD 19.04$ lol wow...
i think shorts have covered motomark. that shortposition from 13.00$ of 42% of float can lead a heavy bounce.
whats your thoguhts? still, this stock is a beast!
all the best
stockfeak001
nice chart clay i hope KATX sees the 0.10$.
have a good weekend.
stockfreak001
i was just like: where did the party board go. lol
it was always on my top now its down. put some $$ in front of the name .
Power-One Launches Dedicated Central Solar Inverter for Asian Market
Datum : 03/12/2010 @ 07h40
Quelle : GlobeNewswire Inc.
Name : Power-One, Inc. (PWER)
Kurs : 10.5725 0.1725 (1.66%) @ 19h35
Power-One Launches Dedicated Central Solar Inverter for Asian Market
Power-One (MM) (NASDAQ:PWER)
Intraday Stock Chart
Heute : Friday 3 December 2010
Click Here for more Power-One (MM) Charts.
Power-One Inc. (Nasdaq:PWER), a leading provider of renewable energy and energy-efficient power conversion and power management solutions, has announced it has launched a newly designed central product specifically targeting the emerging Asian inverter market.
Power-one's new 250kW and 500kW utility grade central inverters have a number of key features, including a very high efficiency of 98.3%; electrolytic capacitor free, leading to longer MTBF (mean time between failures); compact size and weight; touch screen display; and 1000 Voc (open circuit voltage) rating.
"This product offers high performance with affordable capital expenditure and has been specifically designed for the fast growing Asian market," said Paolo Casini, Power-One's Vice President for Marketing. "Its design is the result of the experience we have acquired with more than 50MW of installation in the challenging Asian market."
Power-One is currently the world's second largest manufacturer of solar power inverters. With manufacturing centers in three continents, Power-One and its Aurora brand of solar and wind power inverters, ranging from 2kw to 2.5MW, offer best-in-class product performance and reliability along with a global customer care package.
For more information on Power-One, please visit www.power-one.com.
About Power-One
Power-One designs and manufactures energy-efficient power conversion and power management solutions, including inverters for alternative/renewable energy (solar and wind) and products for routers, data storage and servers, wireless communications, optical networking, semiconductor test equipment, industrial markets and custom applications. Power-One, with headquarters in Camarillo, California, has global sales offices, manufacturing, and R&D operations in Asia, Europe, and the Americas. Power-One is a public company listed on NASDAQ under the ticker symbol PWER. For more information about the Company, please visit www.Power-One.com.
The Power-One, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7338
CONTACT: Power-One, Inc.
Press Enquiries
Jason Nicholls, Global Marketing Communications Manager
+39 (320) 9011 578
Jason.Nicholls@Power-One.com
Investor Relations
Kevin Trosian, Vice President, Finance and Investor Relations
+1 (805) 987-8741
Power-One, Inc. Logo
Market down PWER up 10.80$ your 11.25$ is a very nice price target.
PWER 10.80$ Mister Profit from orion partybahers board sees price target of 11.25$ i buy this.
JAZZ 17.70$ . i saw this stock the first time under 1$. lol
PWER 10.35$ squuuueeezzzeee
thanks as long as the market keeps going PWER will do well. check the PWER board for target prices...
thanks for the chart.
PWER 10.15$ squeeze that 42% short position. lol
what does that mean when a stock is on this list?
PWER 9.60$, squeeze that short interesst? :):)
As of Nov 15, $PWER has a short % interest of 47% (yahoo.finance) Yikes! about 3 hours ago via TweetDeck
PWER 9.60$, squeeze that short interesst? :):)
As of Nov 15, $PWER has a short % interest of 47% (yahoo.finance) Yikes! about 3 hours ago via TweetDeck
yeah lol. definately gotta do that, thanks!
cee you soon.
added some CPIX 7.16$. eom
LCC 11.15$ Swing it.
CPIX new support at 7.20$ Target 9-10$ = Dez.10.2010.